AGMB (AgomAb Therapeutics NV) Other Current Liabilities: $7.64 Mil (As of Dec. 2025)


AGMB AgomAb Therapeutics NV AGMB
14 GF Score
Price $13.08
! 1 Warning Sign
View Full Analysis

What is AgomAb Therapeutics NV Other Current Liabilities?

AgomAb Therapeutics NV AGMB +0.85% 14 Other Current Liabilities is $7.64 Mil as of Dec. 2025. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

AgomAb Therapeutics NV's other current liabilities for the quarter that ended in Dec. 2025 was $7.64 Mil.

AgomAb Therapeutics NV's quarterly other current liabilities declined from Dec. 2024 ($0.00 Mil) to Sep. 2025 ($-0.00 Mil) but then increased from Sep. 2025 ($-0.00 Mil) to Dec. 2025 ($7.64 Mil).

AgomAb Therapeutics NV's annual other current liabilities declined from Dec. 2023 ($1.34 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($7.64 Mil).

AgomAb Therapeutics NV Other Current Liabilities Related Terms

AgomAb Therapeutics NV Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for AgomAb Therapeutics NV's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgomAb Therapeutics NV Other Current Liabilities Chart

AgomAb Therapeutics NV Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
35.86 24.70 1.34 0.00 7.64

AgomAb Therapeutics NV Quarterly Data
Dec21 Dec22 Dec23 Dec24 Sep25 Dec25
Other Current Liabilities Get a 7-Day Free Trial 24.70 1.34 0.00 -0.00 7.64
AGMB
14GF Score
AgomAb Therapeutics NV AGMB
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AgomAb Therapeutics NV Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $7.64 Mil mean?
AgomAb Therapeutics NV (AGMB) has a Other Current Liabilities of $7.64 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on AgomAb Therapeutics NV.
Is AgomAb Therapeutics NV's Other Current Liabilities too high?
AgomAb Therapeutics NV's current Other Current Liabilities is $7.64 Mil. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's Other Current Liabilities compare to DNA and ACRS?
AgomAb Therapeutics NV's Other Current Liabilities of $7.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on AgomAb Therapeutics NV. AgomAb Therapeutics NV's current Other Current Liabilities is $7.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current Other Current Liabilities of $7.64 Mil. The current Other Current Liabilities is $7.64 Mil. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current Other Current Liabilities is $7.64 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AgomAb Therapeutics NV Business Description

Address 1/6 Posthoflei, Antwerp, BEL, 2600
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score

Get the complete analysis for AGMB

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.08
Price